ASP Definition 6 Adds AtheroGenics Inc. to Growing Client Base.

Business Editors

ATLANTA--(BUSINESS WIRE)--Dec. 12, 2000

Definition 6, a leading Application Service Provider (ASP) offering layered e-commerce and communication solutions for large companies with networked affiliates, today announced its newest client: AtheroGenics Inc. (Nasdaq: AGIX), an Atlanta-based bio-pharmaceutical company focused on the discovery, development and commercialization of novel drugs designed to treat and prevent chronic inflammatory diseases.

AtheroGenics enlisted Definition 6 solutionists to complete a full Web site redesign. The revamped Web site will feature streamlined content and a more modern, captivating "look and feel," complete with moving animation, to help the company strengthen its brand and reach more audiences.

"Having just recently completed an initial public offering, we found it was timely to upgrade our Web site, including the enhancement of its navigational tools, so we brought Definition 6 on board to help us rearrange content, add more visual appeal and market the final product to a wider audience," said Chief Financial Officer Mark Colonnese. "Definition 6's advanced consulting and creative design expertise will, we believe, capture the AtheroGenics story and communicate it on a more sophisticated level, ultimately heightening its Internet appeal."

AtheroGenics has developed a proprietary drug discovery technology platform called vascular protectant, or v-protectant, that may be beneficial in treating chronic inflammatory diseases and conditions such as atherosclerosis, asthma and arthritis. The company uses this v-protectant technology to develop drugs that send out small, highly beneficial molecules that block oxidant signals, thereby preventing the production of select inflammatory proteins.

"With our experienced, technically-oriented staff and creative design team, we're more than prepared to help such a noteworthy company reach a wider, more health-concerned audience," said Definition 6 Chief Executive Officer Michael Kogon. "We're thrilled AtheroGenics thought of Definition 6 first after deciding to revamp its Web site, and we look forward to meeting the challenges the company has set forth for us."

About AtheroGenics Inc.

AtheroGenics, through its proprietary vascular protectant drug discovery technology platform, is focused on the discovery, development and commercialization of novel small molecule therapeutics for the treatment of chronic inflammatory diseases such as heart disease (atherosclerosis), asthma and arthritis. The company designed its lead product candidate, AGI-1067, to benefit patients with coronary artery disease, which is atherosclerosis of the heart's blood vessels.

About Definition 6

Founded in 1997, Atlanta-based Definition 6 is a leading Application Service Provider (ASP) offering infrastructure services to companies planning to enhance and extend their business relationships and functions via the Internet. Definition 6 caters to primary organizations and their network of affiliates intending to establish or improve company Web sites. Through its services, including consulting, professional services and an advanced Lease-an-APP(TM) software platform, the company provides all the ancillary resources today's businesses require: application development, e-commerce tools, store fronts, payment processing, content management, legacy integration and marketing support. Please visit www.definition6.com for more information.